Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation

Objectives: To assess the clinical effectiveness and cost-effectiveness of bevacizumab, combined with interferon (IFN), sorafenib tosylate, sunitinib and temsirolimus in the treatment of people with advanced and/or metastatic renal cell carcinoma (RCC). Data sources: Electronic databases, including...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: J Thompson Coon, M Hoyle, C Green, Z Liu, K Welch, T Moxham, K Stein
格式: Artigo
語言:Inglês
出版: NIHR Journals Library 2010-01-01
叢編:Health Technology Assessment
主題:
bevacizumab
sorafenib-tosylate
sunitinib
temsirolimus
renal-cell-carcinoma
systematic-review
economic-evaluation
在線閱讀:https://doi.org/10.3310/hta14020
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍